MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 46,186 shares, a drop of 55.0% from the February 26th total of 102,676 shares. Based on an average trading volume of 118,386 shares, the short-interest ratio is currently 0.4 days. Currently, 2.1% of the shares of the company are sold short.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen lowered MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. HC Wainwright cut their price target on MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $26.50.

MetaVia Stock Down 7.6%

NASDAQ MTVA traded down $0.10 on Friday, hitting $1.22. The stock had a trading volume of 118,310 shares, compared to its average volume of 167,506. The company’s 50-day moving average is $1.81 and its two-hundred day moving average is $6.80. MetaVia has a one year low of $1.21 and a one year high of $23.10. The stock has a market cap of $2.68 million, a price-to-earnings ratio of -0.15 and a beta of 0.33.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.